HRT use following RRBSO was not associated with an increase in risk of BC in BRCA1 carriers (HR 0.52 [95% CI 0.30, 0.92]) and BRCA2 carriers (HR 0.24 [95% CI 0.05, 1.03])BC risk was not increased for both ET and EPT. Here, BRCA2 is linked to breast cancer.